All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

JLL Publishes Report on Trends Shaping the Labs of the Future

March 5, 2018
By Pharmaceutical Technology Editors
News
Article

Pharmaceutical Technology's In the Lab eNewsletter

In the Lab eNewsletterPharmaceutical Technology\'s In the Lab eNewsletter-03-07-2018
Volume 13
Issue 3

JLL, a real estate and investment management firm, recently released a new report on three trends shaping labs for the future of life sciences R&D.

On Feb. 15, 2018, JLL, a real estate and investment management firm, announced the publication of a new report, Journey to the next gen lab, that discussed three trends that are shaping labs for the future of life sciences R&D. These trends include shorter R&D timelines, ongoing cost pressures, and sudden shifts in research priorities, which are driving the way labs are designed and where they are located. Flexible space and access to talent are the keys to agile R&D, according to the company.

According to the report, the average return on R&D investments among large biopharmaceutical firms has declined from 10.1% in 2010 to 3.2% in 2017. Companies are increasingly seeking collaboration and more flexible facilities to remain competitive.

"As a result of organizational cost pressures and a stronger focus on shortening the product lifecycle, R&D real estate is becoming multiuse," said Roger Humphrey, executive managing director and leader of JLL's Life Sciences group, in a company press release. "The result is a drive toward highly flexible and attractive workplaces that appeal to not only scientific, but technical, talent."

JLL uncovered three trends pointing toward the future laboratory space through interviews with 15 leading biopharmaceutical and medical device company executives: designing for flexibility and collaboration; less wet labs, more computational science space; and focus on talent recruitment and retention.

Designing for flexibility and collaboration

Because scientists are dealing with rapidly shifting research priorities, they need space that can be easily reconfigured to accommodate different kinds of research and facilitate interaction with colleagues. Mobile benches and unassigned workspaces, for example, allow for fast changes in personnel and the type of work being performed. Scientists want flexibility that allows them to finish studies as quickly as possible, according to one executive surveyed in the report.

"Behind the scenes, flexibility begins with infrastructure," Humphrey said in the press release. "For example, you can hang retractable electrical cords from the ceiling, so you're not limited to placing equipment against a wall. You can build thick floor slabs into the laboratory corridors and hide technical infrastructure behind a façade, so you can easily move people and equipment."

Less wet labs, more computational science space

Science has become increasingly integrated with data and analytics, as evidenced by the digital transformation of R&D. Wet labs, which were once the dominant space for life sciences research, are shrinking while flex space and office space for computational science are growing because scientists are spending more time analyzing data.

"A traditional R&D facility would consist of mostly lab space and a small proportion of office," Humphrey said. "In a few years, those proportions will likely shift to equal parts web labs, flex space, and office space for the data scientists."

A focus on talent recruitment and retention

JLL has noted in its annual Life Sciences Outlook report that biopharmaceutical companies have intensified their drive to be near leading academic research centers and the supportive R&D ecosystems that surround them. Despite high rents, cities like San Francisco, San Diego, and Boston continue to attract leading companies that want access to resources and talent-including laboratory scientists and the data scientists needed to work with today's voluminous data.

The need for talent is also driving a growing focus on amenities, aesthetic appeal, state-of-the-art equipment, and attention to sustainable design, according to JLL. Rather than hiding R&D space deep inside a facility, some biopharmaceutical companies are creating lab spaces on the perimeters of their facilities to showcase cutting-edge technologies and abundance of natural light.

"We're seeing a growing trend toward creating engaging, attractive labs and office workplaces," Humphrey said. "The goal is to inspire creativity and foster well-being, with natural light, rich amenities, and comfortable places for formal or informal collaboration."

Sourc: JLL

Articles in this issue

Fluid Imaging Introduces New Flow Imaging Nanoparticle Analyzer at Pittcon
Packaged LIMS Solutions
Extraction System for Rapid Sample Preparation of GC/LC Samples
JLL Publishes Report on Trends Shaping the Labs of the Future
Bruker Highlights Analytical Solutions and Systems at Pittcon
Advanced UHPLC Systems Enhance Lab Productivity
Benchtop Mass Spectrometer
Charles River Laboratories Acquires MPI Research
A Technological Foundation for Lab Data Integrity
A Technological Foundation for Lab Data Integrity
Data Integrity: Finding Balance in Today's Lab
Early Drug-Development: What to Consider When Outsourcing Analytical Services
Early Drug-Development: What to Consider When Outsourcing Analytical Services
Recent Videos
Drug Digest: Patient Preference Drives Solid Dosage Trends
Behind the Headlines, Episode 17
Related Content

Data technology background. Abstract background. Connecting dots and lines on dark background. 3D rendering. 4k. | Image Credit: © Dmitry

Emerson Unveils AI Platform for Mission-Critical Industrial Applications

Christopher Cole
May 22nd 2025
Article

Emerson’s purpose-built industrial AI solutions are meant to enhance accessibility and reliability, enabling manufacturers to maximize efficiency and performance from automation systems.


Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


·Mirai Bio and Thermo Fisher are partnering to integrate design, delivery, and CGMP manufacturing for nucleic acid-based therapeutics.  ·The collaboration will leverage Thermo Fisher’s RNA and advanced formulations facility to support scalable development of genetic medicines.  ·Mirai’s machine intelligence platform will be combined with Thermo Fisher’s technical and manufacturing expertise to streamline drug development workflows.

Mirai Bio and Thermo Fisher Partner to Advance Genetic Medicine Manufacturing

Christopher Cole
May 21st 2025
Article

Mirai Bio and Thermo Fisher partner to integrate AI-driven design with CGMP manufacturing, aiming to streamline development of genetic medicines.


Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.


Abnormal plasma cell or b-cell in multiple myeloma emitting paraprotein 3d illustration | Image Credit: © LASZLO - stock.adobe.com

CellCentric Completes $120 Million Series C Funding Round for Multiple Myeloma Treatment Inobrodib

Patrick Lavery
May 21st 2025
Article

Inobrodib is being developed as a first-in-class oral cancer drug that the company says will be able to treat not only multiple myeloma, but other specific cancers as well.


A group of antibiotic pill capsules falling. Healthcare and medical 3D illustration background | Image Credit: © James Thew - stock.adobe.com

Personalised Capsule Machine Unveiled by ACG

Christopher Cole
May 20th 2025
Article

ACG partnered with Art of You to launch the world-first Personalised Capsule Machine, enabling on-demand, customized supplement capsules based on individual health data.

Related Content

Data technology background. Abstract background. Connecting dots and lines on dark background. 3D rendering. 4k. | Image Credit: © Dmitry

Emerson Unveils AI Platform for Mission-Critical Industrial Applications

Christopher Cole
May 22nd 2025
Article

Emerson’s purpose-built industrial AI solutions are meant to enhance accessibility and reliability, enabling manufacturers to maximize efficiency and performance from automation systems.


Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


·Mirai Bio and Thermo Fisher are partnering to integrate design, delivery, and CGMP manufacturing for nucleic acid-based therapeutics.  ·The collaboration will leverage Thermo Fisher’s RNA and advanced formulations facility to support scalable development of genetic medicines.  ·Mirai’s machine intelligence platform will be combined with Thermo Fisher’s technical and manufacturing expertise to streamline drug development workflows.

Mirai Bio and Thermo Fisher Partner to Advance Genetic Medicine Manufacturing

Christopher Cole
May 21st 2025
Article

Mirai Bio and Thermo Fisher partner to integrate AI-driven design with CGMP manufacturing, aiming to streamline development of genetic medicines.


Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.


Abnormal plasma cell or b-cell in multiple myeloma emitting paraprotein 3d illustration | Image Credit: © LASZLO - stock.adobe.com

CellCentric Completes $120 Million Series C Funding Round for Multiple Myeloma Treatment Inobrodib

Patrick Lavery
May 21st 2025
Article

Inobrodib is being developed as a first-in-class oral cancer drug that the company says will be able to treat not only multiple myeloma, but other specific cancers as well.


A group of antibiotic pill capsules falling. Healthcare and medical 3D illustration background | Image Credit: © James Thew - stock.adobe.com

Personalised Capsule Machine Unveiled by ACG

Christopher Cole
May 20th 2025
Article

ACG partnered with Art of You to launch the world-first Personalised Capsule Machine, enabling on-demand, customized supplement capsules based on individual health data.

About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.